Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826).

We report a prespecified subset analysis of patients enrolled in the phase 3 SWOG S1826 trial to evaluate outcomes based on EBV status and histologic subtype in patients treated with N-AVD (nivolumab-AVD) or BV-AVD (brentuximab vedotin-AVD).

我们报告了在 III 期 SWOG S1826 试验中预先指定的患者亚组分析，以评估接受 N-AVD (nivolumab-AVD) 或 BV-AVD (brentuximab vedotin-AVD) 治疗的患者基于 EBV 状态和组织学亚型的治疗结果。

In the phase 3 SWOG S1826 trial, patients with stage III to IV cHL were randomized to N-AVD or BV-AVD treatment.

在 III 期 SWOG S1826 试验中，III 至 IV 期 cHL 患者被随机分配接受 N-AVD 或 BV-AVD 治疗。

Of 970 eligible patients, 522 had known EBV status.

在 970 名符合条件的患者中，有 522 名患者的 EBV 状态已知。

N-AVD improved 3-year progression-free survival(PFS) in patients who were EBV+ (91% vs 70%; hazard ratio[HR], 0.30; P = .01) and EBV- (90% vs 84%; HR, 0.64; P = .09).

N-AVD 改善了 EBV 阳性患者的 3 年无进展生存期 (PFS)（91% 对比 70%；风险比 [HR]，0.30；P = .01）以及 EBV 阴性患者（90% 对比 84%；HR，0.64；P = .09）。

Among 664 patients with slides available for histology review, 102 (15.4%) had non-NS histologic subtypes.

在 664 名有组织学复审幻灯片的患者中，有 102 名（15.4%）患者具有非结节硬化型组织学亚型。

N-AVD prolonged 3-year PFS in patients with non-NS histologic subtype (86% vs 63%; HR, 0.33; P = .006) and NS histologic subtype (93% vs 86%; HR, 0.53; P = .01).

N-AVD 延长了非结节硬化型组织学亚型患者的 3 年无进展生存期 (PFS)（86% 对比 63%；HR，0.33；P = .006）以及结节硬化型组织学亚型患者的 3 年无进展生存期（93% 对比 86%；HR，0.53；P = .01）。

Non-NS histologic subtype was independently associated with inferior outcomes (HR, 2.54; P< .0001) after adjusting for treatment in the entire cohort.

在调整整个队列中的治疗后，非结节硬化型组织学亚型独立地与较差的结果相关（HR，2.54；P< .0001）。

However, N-AVD treatment still had favorable PFS within this high-risk group.

然而，在这个高风险组中，N-AVD治疗仍然有良好的无进展生存期（PFS）表现。

In addition, patients with EBV+ status or non-NS histologic subtype cHL treated with BV-AVD had significantly worse PFS (HR, 1.97; P = .03 for EBV and HR, 3.08; P< .0001 for histology).

此外，接受BV-AVD治疗的EBV阳性状态或非NS组织学亚型的经典霍奇金淋巴瘤（cHL）患者的PFS显著较差（EBV的HR为1.97，P = .03；组织学的HR为3.08，P< .0001）。

N-AVD substantially abrogated the historically poor prognosis associated with EBV+ status and non-NS histologic subtype in advanced-stage cHL.

N-AVD显著减轻了与EBV阳性状态和非NS组织学亚型相关的晚期cHL的历史上不良预后。

These results support N-AVD as a frontline standard of care, particularly in high-risk biologic subgroups.

这些结果支持将N-AVD作为一线标准治疗，特别是在高风险的生物亚组中。

This trial was registered at www.clinicaltrials.gov as NCT03907488.

这项试验已在www.clinicaltrials.gov上注册，注册号为NCT03907488。